Detection of SARS-CoV-2 neutralizing antibodies in nasal fluids
VIRUS
Nasal fluid was collected by swabbing from both nostrils before and immediately or 6 h after the study product application in both the NAS and placebo groups (see Fig. Assessment of SARS-CoV-2 neutralizing antibodies in nasal fluids before and after a placebo or NAS application. SARS-CoV-2 neutralizing antibodies in nasal fluids swabbed from pre- and post-product administration were detected using the cPass SARS-CoV-2 surrogate virus neutralization test. (The neutralizing antibodies against ancestral, Delta, or Omicron BA.2 RBD proteins were detected based on the signal inhibition percent (SIP) of the cPass assay. The SIP values against the ancestral variant in the nasal fluid from the NAS group were significantly increased from baseline at both time points (median of baseline vs. immediate time point: 12.41% vs. 97.58%; 